Our study sought to help address this question by reviewing multi-institutional data for patients with small, node-negative, HER2+ breast cancer to compare clinical outcomes between those who go untreated versus those who receive adjuvant trastuzumab therapy, with or without chemotherapy. Here, ERBB2 is linked to breast carcinoma.